Study of oxidative stress in ovarian cancer

• Autorzy: Rashmi B.V. , Mukund T.B. , Shubhangi D.M. , Neelam Y. , Vinayak P.W.
• Języki publikacji: EN

Abstrakty

EN

Background: Ovarian cancer is the fifth most common form of cancer in the world and is often asymptomatic in its early stages. Development of ovarian cancer-specific biomarkers for the early detection of disease could improve the current dismal survival rate. Evaluation of serum carbohydrate antigen 125 (CA125), alkaline phosphatase (ALP) and oxidative stress in ovarian carcinoma patients may improve the prognosis of the disease through earlier detection. Aim of the study: The aim of this study was to find the relative risk of ovarian cancer in patients screened for CA125, ALP, Nitric oxide (NO) and Malondialdehyde (MDA) as a marker for lipid peroxidation. Material and methods: 451 subjects with ovarian cancer were screened for serum CA125 levels using a chemiluminescence analyser, out of which 164 showed values above 21 U/ml. 80 subjects with higher values were further analysed for MDA and NO using spectrophotometry and AL P by fully automated chemistry analyser. Results: The selected 80 subjects with CA125 values above 74 U/ml had increased ALP, NO and MDA, also showing positive correlation amongst these parameters. Conclusions: Benefits of CA125 screening vary with age group according to blood CA125 levels. Enzyme ALP levels are elevated with higher values of CA125. MDA and NO indicate oxidative stress and increase as the ovarian marker values increase. Positive correlation amongst the parameters indicates a significant increase in oxidative stress in ovarian cancer. For women with various CA125 levels in different age groups, screening and treatment depends upon individual decision and clinical examination.

• Wydawca: -
• Czasopismo: Medical Science Pulse
• Rocznik: 2018
• Tom: 12
• Numer: 4
• Opis fizyczny: p.4-8,fig.,ref.

Twórcy

autor

Rashmi B.V.

• Department of Biochemistry, Grant Government Medical College and Sir J.J. Group of Hospitals, Mumbai, India

autor

Mukund T.B.

• Department of Surgery, Grant Government Medical College and Sir J.J. Group of Hospitals, Mumbai, India

autor

Shubhangi D.M.

• Department of Biochemistry, Grant Government Medical College and Sir J.J. Group of Hospitals, Mumbai, India

autor

Neelam Y.

• Department of Biochemistry, Grant Government Medical College and Sir J.J. Group of Hospitals, Mumbai, India

autor

Vinayak P.W.

• Department of Biochemistry, Grant Government Medical College and Sir J.J. Group of Hospitals, Mumbai, India

Bibliografia

• 1. Anshu AK, Kumar S, Sinha S, Nath A, Priyanka, et al. Assessment of MDA in adjuvant with CA-125 in early ovarian cancer detection. IJDR 2015; 5(4): 4084–4091.
• 2. Fritsche HA , Bast RC. Editorial. CA 125 in ovarian cancer: advances and controversy. Clin Chem 1998; 44(7): 1379–1380.
• 3. Orsaria M, Londerob AP, Marzinottoa S, Di Loretoa C, Marchesonic D, et al. Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma. Cancer Biomark 2016; 17: 479–486.
• 4. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival – a review of the epidemiological literature. J Ovarian Res 2009; 2: 13.
• 5. Pepin K, del Carmen M, Brown A, Dizon DS. CA 125 and epithelial ovarian cancer: role in screening, diagnosis and surveillance. Am J Hematol Onc 2014; 10(6): 22–29.
• 6. Kim SH, Shin KH, Moon SH, Jang J, Kim HS, et al. Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. Cancer Med 2017; 6(6): 1311–1322.
• 7. Belotte J, Fletcher NM, Awonuga AO , Alexis M, Abu-Soud HM, et al. The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer. Reprod Sci 2014; 21(4): 503–508.
• 8. Falfushynska HI. Detection of oxidative stress, apoptosis and molecular lesions in human ovarian cancer cells. IJMMR 2016; 2(1): 13–18.
• 9. Li L, Zhu L, Hao B, Gao W, Wang Q, et al. iNO S-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer. Oncotarget 2017; 8(20): 33047–33063.
• 10. Ben-Arie A, Hagay Z, Ben-Hur H, Open M, Dgani R. Elevated serum alkaline phosphatase may enable early diagnosis of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999; 86: 69–71.
• 11. Sharma S, Shrivastav A, Shrivastav BR . Clinical evidences of oxidative stress as a biomarker in various types of cancers: a review. Int J Pharm Sci Res 2014; 5(3): 657–665.
• 12. Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med 2007; 1(4): 513–523.
• 13. Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH , Tholander B, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer - updated guidelines from the european group on tumor markers. Int J Gynecol Cancer 2016; 26(1): 43–51.
• 14. Eagle K, Ledermann JA. Tumor markers in ovarian malignancies. The Oncologist 1997; 2: 324–329.
• 15. Didziapetriene J, Bublevič J, Smailytė G, Kazbarienė B, Stukas R. Significance of blood serum catalase activity and malondialdehyde level for survival prognosis of ovarian cancer patients. Medicina 2014; Issue 50204: 208.
• 16. Verma Arti, Tiwari Sunita, Sankhwar Pusphlata, Dwivedi Anila, Tripathi Dinesh, Srivastava Rohit Kumar. Role of cancer antigen-125 and oxidative stress in clinical stages of pre-operative ovarian carcinoma. IJBPR 2015; 6(7): 526–531.

Identyfikatory

DOI

10.5604/01.3001.0012.7047